Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia

Mehrdad Hefazi, Mark R Litzow Division of Hematology, Mayo Clinic, Rochester, MN, USA Abstract: Acute lymphoblastic leukemia (ALL) is a hematologic malignancy arising from precursors of the lymphoid lineage. Conventional cytotoxic chemotherapies have resulted in high cure rates of up to 90% in pedia...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hefazi M, Litzow MR
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Acute lymphoblastic leukemia minimal residual disease hematopoietic cell transplantation Philadelphia chromosome monoclonal antibodies. Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/1f56f5383c094dbaa758217e5d45db1a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1f56f5383c094dbaa758217e5d45db1a
record_format	dspace
spelling	oai:doaj.org-article:1f56f5383c094dbaa758217e5d45db1a2021-12-02T01:50:28ZRecent advances in the biology and treatment of B-cell acute lymphoblastic leukemia1179-9889https://doaj.org/article/1f56f5383c094dbaa758217e5d45db1a2018-09-01T00:00:00Zhttps://www.dovepress.com/recent-advances-in-the-biology-and-treatment-of-b-cell-acute-lymphobla-peer-reviewed-article-BLCTThttps://doaj.org/toc/1179-9889Mehrdad Hefazi, Mark R Litzow Division of Hematology, Mayo Clinic, Rochester, MN, USA Abstract: Acute lymphoblastic leukemia (ALL) is a hematologic malignancy arising from precursors of the lymphoid lineage. Conventional cytotoxic chemotherapies have resulted in high cure rates of up to 90% in pediatric ALL, but the outcomes for adult patients remain suboptimal with 5-year survival rates of only 30%–40%. Over the last decade, major advances have been made in our understanding and management of ALL. Identification of new prognostic genomic markers and incorporation of minimal residual diseases’ assessment into therapeutic protocols have improved risk stratification and treatment strategies. The use of pediatric-inspired regimens for adolescent and young adults, and the advent of tyrosine kinase inhibitors and novel targeted therapies, including monoclonal antibodies and chimeric antigen receptor T cells, have redefined the therapeutic paradigm of ALL, and significantly improved the outcomes. In this article, we will provide an overview of the current knowledge regarding the biology and treatment of ALL, and highlight recent diagnostic and therapeutic advances made in this area over the past 5 years. Keywords: acute lymphoblastic leukemia, minimal residual disease, hematopoietic cell transplantation, Philadelphia chromosome, monoclonal antibodiesHefazi MLitzow MRDove Medical PressarticleAcute lymphoblastic leukemiaminimal residual diseasehematopoietic cell transplantationPhiladelphia chromosomemonoclonal antibodies.Diseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol Volume 8, Pp 47-61 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Acute lymphoblastic leukemia minimal residual disease hematopoietic cell transplantation Philadelphia chromosome monoclonal antibodies. Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Acute lymphoblastic leukemia minimal residual disease hematopoietic cell transplantation Philadelphia chromosome monoclonal antibodies. Diseases of the blood and blood-forming organs RC633-647.5 Hefazi M Litzow MR Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia
description	Mehrdad Hefazi, Mark R Litzow Division of Hematology, Mayo Clinic, Rochester, MN, USA Abstract: Acute lymphoblastic leukemia (ALL) is a hematologic malignancy arising from precursors of the lymphoid lineage. Conventional cytotoxic chemotherapies have resulted in high cure rates of up to 90% in pediatric ALL, but the outcomes for adult patients remain suboptimal with 5-year survival rates of only 30%–40%. Over the last decade, major advances have been made in our understanding and management of ALL. Identification of new prognostic genomic markers and incorporation of minimal residual diseases’ assessment into therapeutic protocols have improved risk stratification and treatment strategies. The use of pediatric-inspired regimens for adolescent and young adults, and the advent of tyrosine kinase inhibitors and novel targeted therapies, including monoclonal antibodies and chimeric antigen receptor T cells, have redefined the therapeutic paradigm of ALL, and significantly improved the outcomes. In this article, we will provide an overview of the current knowledge regarding the biology and treatment of ALL, and highlight recent diagnostic and therapeutic advances made in this area over the past 5 years. Keywords: acute lymphoblastic leukemia, minimal residual disease, hematopoietic cell transplantation, Philadelphia chromosome, monoclonal antibodies
format	article
author	Hefazi M Litzow MR
author_facet	Hefazi M Litzow MR
author_sort	Hefazi M
title	Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia
title_short	Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia
title_full	Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia
title_fullStr	Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia
title_full_unstemmed	Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia
title_sort	recent advances in the biology and treatment of b-cell acute lymphoblastic leukemia
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/1f56f5383c094dbaa758217e5d45db1a
work_keys_str_mv	AT hefazim recentadvancesinthebiologyandtreatmentofbcellacutelymphoblasticleukemia AT litzowmr recentadvancesinthebiologyandtreatmentofbcellacutelymphoblasticleukemia
_version_	1718402818818179072

Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia

Ejemplares similares